Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vidaza

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

- PMLiVE

Celgene creates art gallery to highlight impact of psoriasis

Life's an Itch gallery will be used at meetings and medical conferences

Celgene building

Celgene: Patient voice often underrepresented in pricing debates

Dr Jackie Fouse says in the interests of transparency patients should be more involved

Celgene building

Wales backs NHS use of Abraxane despite NICE rejection

Overrules UK decision and will maintain access to Celgene’s pancreatic cancer drug

- PMLiVE

Celgene uses ‘video views’ map in arthritis awareness drive

Be Counted! campaign highlights US views of its short films

- PMLiVE

Celgene makes changes to its senior leadership team

Bob Hugin, Mark Alles, Jacqualyn Fouse and Scott Smith take on new roles

- PMLiVE

Bayer forms JV with gene editing firm CRISPR

$300m investment to find new therapies for blood disorders, blindness and congenital heart disease

- PMLiVE

AZ confirms interest in Acerta takeover

Possible acquisition of Netherlands-based cancer drug developer may be worth more than $5bn

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links